Atlas Trials

Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver

Clinical trial NCT00274495 · TERMINATED

Trial details

NCT number
NCT00274495
Sponsor
Beth Israel Medical Center
Status
TERMINATED
Phase
Phase 4
Study type
INTERVENTIONAL
Chronic Hepatitis C InfectionFatty Liver
Start date
2006-01-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.